Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis
Figure 1
Frequency of myeloid and plasmacytoid dendritic cells in peripheral blood.
Frequency of myeloid and plasmacytoid dendritic cells (MDCs and PDCs) was determined in frozen cells from relapsing-remitting MS patients using flow cytometry. A. Dead cells were excluded using a viability dye (LIVE/DEAD), followed by exclusion of cells expressing mature hematopoietic lineages using a Lineage cocktail (CQ). PDCs and MDCs were identified based on their expression of CD123 and CD11c, respectively. B–C. Frequency of MDCs and PDCs in untreated MS patients (UNT) and MS patients treated with natalizumab (NTZ) or interferon-β (IFN) from Cohort 1 (B) and Cohort 2 (C). Graph shows mean, interquartile range, and min-max range. Frequency of PDCs in NTZ-treated patients in relation to duration of treatment in patients from Cohort 1 (filled) or Cohort 2 (open) (D).